Global Vaccine Market Size Was Worth US$ 46.88 Billion in 2019, and It Is Estimated To Reach A Valuation of US$ 104.87 Billion by The End of 2027

Global Vaccine Market Size Was Worth US$ 46.88 Billion in 2019, and It Is Estimated To Reach A Valuation of US$ 104.87 Billion by The End of 2027

October 14, 2021, New York, USA -

The Global Live Vaccines Market Forecast: 

Vaccines are the strongest and cost-effective method of protecting billions of people across the globe. Vaccine development holds the potential to improve health by reducing the threat of life-threatening infectious illnesses among people living in wealthy nations. World Health Organization (WHO) declares that vaccination awareness and government-sponsored initiatives have been instrumental in preventing between 2 and 3 million deaths each year. More investments, in conjunction with mergers and partnerships between companies, increase the sales and production of vaccines across the globe.

The global market for vaccines in size reached USD 46.88 billion in 2019. It is expected to grow to USD 104.87 billion by 2027. This will show a CAGR of 10.7% during the forecasted time.

One of the most significant issues facing organizations and corporations around the world is the constant experimentation and testing of efficient vaccines that fight against illnesses like malaria, HIV, and tuberculosis. Pharmaceutical and government agencies are making huge efforts in the establishment of plans for the development of solutions for these illnesses. In addition, the increasing incidence of endemic and infectious diseases will likely drive the development of the market over the forecast time. For example, the COVID-19 epidemic in 2019-2020 was responsible for over 80 million people worldwide.

Market Drivers and Market Trends for the Global Live Vaccines Market:

Latest Trends:

An alarming number of Americans are suffering from pneumonia each year. This makes it necessary to provide adequate vaccines to protect against the disease. Rapid immunization is essential due to the increasing vulnerability of the geriatric population and children to deadly diseases. International bodies like UNICEF and PAHO have provided millions of vaccine doses to countries in dire need. UNICEF news reports that it shipped more than 260,000 vaccines doses to combat measles to Fiji, Samoa, and Tonga in November 2019. These organizations have helped to decrease the incidence of many diseases by procuring large amounts of vaccine doses. This has resulted in an increase in the immunity of the population to various infectious diseases.

Driving Factors:

The increasing supply of vaccines around the world is a key driver for market growth. It helps to address unmet medical needs and adhere to immunization policies. International organizations, hospitals, pharmaceutical companies, and foundations all have a strong focus on providing affordable and consistent immunizations to people around the world. All countries have government surveillance to ensure that everyone is vaccinated with the recommended vaccines at minimum cost. The Universal Immunization Programme (UPI), for instance, distributed the pneumococcal conjugate vaccination to 21 million children in Himachal Pradesh and Bihar in India. The rising market value of these vaccines is due to the increasing demand. Government funding and investments by companies are also helping to boost the R&D sector in order to launch new products.

The competitive pipeline, which includes products from both established and major players, is another key factor in the growth of the vaccine market. The market is large and diverse, so players have difficulty getting approvals from regulatory agencies for their products. Every company is accepting the challenge of launching new products on the market and continuous R&D. Bavarian Nordic, Novavax, and Inovio Pharmaceuticals are just a few of the companies that will have the opportunity to sell their pipeline products over the next few years. Potential pipeline candidates include Merck, Sanofi, and Pfizer, which are all expected to grow and contribute positively to market growth.

The Key Market Segmentation of the Global Live Vaccines Market: 

Global Live Vaccines Market can be divided into Technology, Type, Disease Indication, Route of Administration, Patient Type and Geographical landscapes, etc. 

Live Vaccines Market Segmentation By Technology Type:

Conjugate vaccines

Inactivated and subunit vaccines

Live attenuated vaccines

Recombinant vaccines

Toxoid vaccines

Live Vaccines Market Segmentation By Technology Type:

Monovalent vaccines

Multivalent vaccines

Live Vaccines Market Segmentation By Disease Indication:

Pneumococcal disease




Meningococcal disease






Herpes zoster

Other disease indications

Live Vaccines Market Segmentation By Route of Administration:

Intramuscular and subcutaneous administration

Oral administration

Other routes of administration

Live Vaccines Market Segmentation By Route of Patient Type:

Pediatric patients

Adult patients

Live Vaccines Market Segmentation By Geographical Landscape:

North America


Asia Pacific

South America

The Middle East and Africa

Major Key Players in the Global Live Vaccines Market Are:

GlaxoSmithKline plc (UK) 

AstraZeneca (UK)

Serum Institute of India Pvt. Ltd. (India) 

Pfizer, Inc. (US) 

Emergent BioSolutions, Inc. (US) 

Johnson & Johnson (US) 

Sanofi Pasteur (France) 

Merck & Co., Inc. (US)

CSL Limited (Australia)

Bavarian Nordic (Denmark)

Biological E (India)

Valneva SE (France)

Mitsubishi Tanabe Pharma Corporation (Japan), 

Daiichi Sankyo Company 

Bharat Biotech (India) 

Sinovac Biotech Ltd. (China),

Incepta Vaccine Ltd. (Bangladesh) 

Limited (Japan)

Panacea Biotec (India) 

VBI Vaccines Inc. (US)

PT Bio Farma (Brazil)

The Covid-19 Impact Analysis: 

More than 200 countries are currently affected by the COVID-19 pandemic. The outbreak has prompted manufacturers to improve production and increase supply. UNICEF, WHO, and PAHO have stopped all regular immunization campaigns due to the pandemic. UNICEF reported that 99 countries had stopped participating in immunization campaigns against measles/rubella and meningococcal.

A decrease in vaccination rates and the suspension of immunization campaigns have placed enormous strain on healthcare systems, increasing mortality rates and making people more susceptible to deadly antigens. This situation will have far more severe consequences than the pandemic. GAVI estimates that 13.5 million people in the least developed countries will be affected by the cessation of immunizations. A decrease in the pneumococcal vaccine supply could increase the incidence of pneumococcal diseases, which may lead to higher mortality rates.

The COVID-19 epidemic has resulted in a significant drop in vaccine adoption. The low- and middle-income countries have seen a slower rate of vaccination. The market will see a positive increase in 2020 due to an increase in R&D investments against diseases. The launch of new products will also be a factor in the market's growth over the forecast period. Pfizer, Johnson and Johnson, and other major players have several potential vaccine candidates in their pipeline.

Need Help?

Please fill form below:

Contact Us

99 WALL STREET #2124 NEW YORK, NY 10005